Objective: To identify the genetic cause of pontocerebellar hypoplasia type III (PCH3).
Results:
The affected individuals presented with severe global developmental delay and seizures starting in the first year of life. Brain MRI of an affected individual showed diffuse atrophy of the cerebrum, cerebellum, and brainstem. Genome-wide single nucleotide polymorphism analysis confirmed the linkage to chromosome 7q we previously reported, and showed no other genomic areas of linkage. Whole-exome sequencing of 2 affected individuals identified a shared homozygous, nonsense variant in the PCLO (piccolo) gene. This variant segregated with the disease phenotype in the pedigree was rare in the population and was predicted to eliminate the PDZ and C2 domains in the C-terminus of the protein. RNA sequencing data of human fetal brain showed that PCLO was moderately expressed in the developing cerebral cortex.
Conclusions: Here, we show that a homozygous, nonsense PCLO mutation underlies the autosomal recessive neurodegenerative disorder, PCH3. PCLO is a component of the presynaptic cytoskeletal matrix, and is thought to be involved in regulation of presynaptic proteins and synaptic vesicles. Our findings suggest that PCLO is crucial for the development and survival of a wide range of neuronal types in the human brain. Neurology ® 2015;84:1745-1750 GLOSSARY dbSNP 5 Single Nucleotide Polymorphism Database; ExAC 5 Exome Aggregation Consortium; FPKM 5 fragments per kilobase of exon per million fragments mapped; GATK 5 Genome Analysis Toolkit; indel 5 insertion-deletion; LOD 5 logarithm of odds; NHLBI 5 National Heart, Lung, and Blood Institute; PCH 5 pontocerebellar hypoplasia; PCH3 5 pontocerebellar hypoplasia type III.
affected children included reduced cerebral white matter volume, hypotonia, hyperreflexia, and seizures with onset in the first year of life.
The main objective of this study was to determine the genetic basis of PCH3. We extended the study of the previously reported pedigree, and identified a homozygous nonsense mutation in the PCLO gene to be the cause of PCH3.
METHODS Standard protocol approvals, registrations, and patient consents. Informed consent was obtained from participating individuals or their legal guardians, and research was performed according to institutional, national, and international human subject research guidelines.
Study subjects. The clinical description and linkage analysis of part of the family was previously published. 3 Genetic studies. Genomic DNA samples were extracted from peripheral blood according to standard protocols. DNA samples were genotyped using Illumina HumanHap550-Duo BeadChip microarrays (Illumina, Inc., San Diego, CA). The data were visualized using the dChip software package. 4, 5 Multipoint logarithm of odds (LOD) scores were calculated using MERLIN, 6 assuming a recessive mode of disease inheritance, full penetrance, and a disease allele frequency of 0.0001. Whole-exome sequencing in 2 affected individuals was performed using 2 different methods as follows: RNA sequencing. Messenger RNA sequencing data from human fetal (9 weeks postconception) cerebral cortex was obtained as previously described. 7 
RESULTS
We studied a consanguineous pedigree with a total of 4 affected children from the Sultanate of Oman (figure 1A). I:1 and I:2 are first cousins once removed. I:3 is related to I:1 and I:2, although it is not known exactly how. Part of the pedigree (I:1, I:2, and their children) and detailed clinical information of 3 of the affected children (II:2, II:6, and II:8) were published previously. 3 Briefly, the affected individuals presented with severe global developmental delay and seizures starting in the first year of life. Neurologic examination was remarkable for truncal hypotonia with increased deep tendon reflexes. II:2 had pale optic discs and II:6 had optic atrophy. Brain MRI of one of the affected individuals (II:2) showed diffuse atrophy of the cerebrum, cerebellum, and brainstem (figure 1B). The white matter volume was diminished, and the corpus callosum was thin. However, the state of myelination was age-appropriate. Subsequently, the father (I:2) remarried to I:3, and had a girl (II:9) who had the same neurologic presentation as her affected half-siblings. She is currently 11 years of age and started having generalized seizures starting at 9 months.
We previously mapped the condition to chromosome 7q11-21 using genome-wide microsatellite marker analysis. 3 Since then, we performed genome-wide SNP analysis to confirm the linkage. We performed SNP genotyping on 7 individuals in the pedigree (I:1, I:2, II:2, II:3, II:6, II:7, and II:8). Genome-wide linkage analysis yielded a maximum multipoint LOD score of 2.958 for the 7q11-21 region. The next highest LOD score in the genome was less than 1.5, thus confirming it as the candidate locus ( figure 1C) .
We then performed whole-exome sequencing on 2 affected individuals (II:2 and II:8). After filtering the identified variants for call quality, potential pathogenicity, population frequency, and localization within the candidate interval, only a single candidate variant shared between both individuals remained (table) . The candidate variant, chr7:82579280 G.A (hg 19), is located within exon 6 of the PCLO (piccolo) gene and is predicted to cause a premature stop codon (NM_033026.5:c.10624C.T; p.R3542X). In individual II:8, 2 other variants persisted after filtering. They were chr7:72396170 GCGCCGCGCTCCCCAC.G within the POM121 gene and chr7:76062783 T.A within the ZP3 gene. The POM121 variant was found to be homozygous in 4 individuals in the Exome Aggregation Consortium (ExAC) Browser (November 2014), and the ZP3 variant was found to be homozygous in an individual without a neurologic condition in our in-house exome data. Thus, these 2 variants were ruled out. Sanger sequencing confirmed that the PCLO variant segregates with the disease in the family ( figure 1A ). There are 2 PCLO isoforms annotated (NM_014510.2, encoding 4,935 amino acids, and NM_033026.5, encoding 5,142 amino acids), and this variant affects both isoforms. This variant is not present in the 1000 Genomes (November 2014), the Exome Variant Server (November 2014), the ExAC Figure 1 The pedigree studied and identification of a homozygous PCLO mutation Browser (November 2014), or in 122 Omani control chromosomes. In the Exome Variant Server, only 2 high-impact PCLO variants (nonsense, frameshift, or canonical splice site) are listed in one individual each, and both are heterozygous. In the ExAC Browser, there is no high-impact PCLO variant that is homozygous. This supports the notion that homozygous high-impact variants in PCLO could be deleterious. The PCLO protein has several identifiable domains. These include 2 piccolo zinc finger domains, a PDZ domain, and 2 C2 domains ( figure 1D ). The mutation localizes proximal to the PDZ and C2 domains, and is expected to eliminate these domains even if a truncated protein is produced. Next, we investigated expression of PCLO in the developing human brain. Messenger RNA sequencing of the developing cerebral cortex from human fetal brain (9 weeks postconception) showed that PCLO is expressed at a moderate level (figure 2), approximately similar to that of a related gene, BSN (bassoon), and another synaptic protein gene, GRIK2 (glutamate receptor, ionotropic, kainate 2), which has been implicated in an intellectual disability syndrome. 8 We also analyzed an additional RNA sequencing dataset of human fetal brain (13-16 weeks postconception). 9 In this dataset, PCLO expression was very low in the ventricular zone (0.48 FPKM [fragments per kilobase of exon per million fragments mapped]), and moderately high in the cortical plate (12.10 FPKM) . This dataset also shows that the level of expression and spatial pattern are similar to those of BSN (VZ 5 1.45 FPKM; CP 5 10.64 FPKM), and GRIK2 (VZ 5 0.63 FPKM; CP 5 19.03 FPKM). These data are consistent with known roles of these proteins in mature synapses. We searched for additional deleterious PCLO alleles in our database of .500 exomes from individuals with various neurodevelopmental disorders, but did not find other convincing disease-causing mutations.
DISCUSSION Our data show that a homozygous, nonsense mutation in the PCLO gene causes PCH3. Despite the term "pontocerebellar hypoplasia," it is difficult to determine whether the condition in this family represents true hypoplasia of the pons and cerebellum, as no brain imaging of the affected individuals at an early age is available for comparison. The imaging findings are suggestive of atrophic changes, and so it may be more accurate to consider this entity as a degenerative disorder affecting both the cerebrum and cerebellum. PCLO is a gene unique to vertebrates, which encodes a large protein component of the presynaptic active zone, a specialized area mediating neurotransmitter release. [10] [11] [12] Piccolo has been found to interact with and control the assembly of presynaptic F-actin, which is important for the regulation of the synaptic vesicle cycle, suggesting that it may modulate neurotransmitter release through this interaction. 13 It is interesting to note that the mutation in PCLO in humans leads not only to synaptic dysfunction but also to loss of cerebral and cerebellar volume, suggesting severe neuronal loss. Recently, piccolo and bassoon, another active zone component structurally related to piccolo, were shown to control ubiquitination of synapse proteins, and their loss led to aberrant degradation of multiple presynaptic proteins and eventually degeneration of synapses.
14 Synaptic activity is essential for preventing apoptosis, 15 so it is conceivable that degeneration of synapses due to absent PCLO triggers an apoptotic signal in neurons. For example, biallelic deletions of GRID2, which encodes a synaptic protein in Purkinje cells, also cause severe cerebellar atrophy in humans. 16 Engineered mice that lack Pclo exon 14 have been reported. 17 The homozygous mutant mice show a modest decrease in postnatal survival and weight, but interestingly do not show ultrastructural changes in synapses, defects in neurotransmission, or seizures. 17 Although detailed neuroanatomical description of these mice has not been reported, the phenotype appears to be much milder compared to the individuals with the PCLO mutation described herein. Mouse isoforms of Pclo lacking exon 14 have been suggested. 13 For example, the retinal photoreceptor and bipolar cell ribbon synapses express a unique Pclo isoform that is not affected by the absence of exon 14. 18 This could, in part, explain the phenotypic difference between mice and humans, and raises the possibility that different PCLO isoforms have tissue-specific roles in the human CNS.
The affected individuals reported herein all had seizures starting during infancy. This could be explained by disruption of the equilibrium between excitatory and inhibitory neurotransmitter signaling due to neuronal loss, or by the effect of the PCLO mutation on synaptic vesicle recycling, which in turn might impair regulation of neuronal synchrony.
We did not find additional mutant alleles in our large cohort of neurodevelopmental disorders, but an individual from Turkey was reported to have a remarkably similar clinical presentation and displayed linkage to the chromosomal region encompassing PCLO, suggesting possible allelism. 19 Since the brain MRI findings of PCH3 are rather nonspecific, with cerebral and cerebellar atrophy, it is possible that PCH3 is underdiagnosed. Molecular studies of additional cases of PCH3 will help delineate its full clinical spectrum and further elucidate the role of PCLO in the human brain. You asked and we listened. As of January 1, 2015, your robust AAN membership package includes FREE* access to online learning programs designed specifically to help you take the necessary steps toward fulfilling your maintenance of certification (MOC) requirements as mandated by the ABPN: NeuroPI SM , NeuroSAE ® , NeuroLearn SM .
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